Opiranserin

DB16271InvestigationalSmall molecule

Opiranserin is under investigation in clinical trial NCT03997838 (Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-operative Pain Following Abdominoplasty).

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2A and Sodium- and chloride-dependent glycine transporter 2
Curator reviewed
Formula / weight: C₂₁H₃₄N₂O₅ · 394.512 g/mol (avg)
Also known as: Vvz-149 free base

Resolves to

Compound

UNIIAP031EC2NICAS1441000-45-8ChEMBLCHEMBL4228903

Structure

InChIKeyJQUVQWMHZSYCRQ-UHFFFAOYSA-NSMILESCCCCOC1=C(OC)C=C(C=C1OC)C(=O)NCC1(CCOCC1)N(C)C

Targets

P28223HTR2AQ9Y345SLC6A5

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Opiranserin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account